A selected listing of trials undertaken at The Skin Hospital:

Sponsor, Protocol ID, Long title

Abbvie, M16046, A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects with Moderate to Severe Atopic Dermatitis

Abbvie, M19850, A Phase 3b, open-label treatment extension study of upadacitinib for the treatment of adult subjects with moderate to severe atopic dermatitis who completed treatment in Study M16-046

Abbvie, M18891, A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis

Arcutis, ARQ-154-204, A Phase 2b, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Adolescents and Adults with Scalp and Body Psoriasis

Arcutis, ARQ-252-205, A Phase 1 and 2, Multiple Dose and 12-Week, Parallel Group, Double Blind, Dose Ranging, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-252 Cream 0.1% and ARQ-252 Cream 0.3% in Subjects with Chronic Hand Eczema

Botanix, BTX.2018.003, A Randomized, Double-Blind, Vehicle-Controlled Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients with Moderate Atopic Dermatitis

Dermira, DRM06-AD04/J2T-DM-KGAB, A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis

Dermira, DRM06-AD17, An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis

Lilly, I4V-MC-JAHN(c), A Phase 3 Multicenter, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Adult Patients with Atopic Dermatitis

Lilly, I4V-MC-JAHN(7.1), Protocol Addendum I4V-MC-JAHN(7.1) A Phase 3 Multicenter, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Adult

Patients with Atopic Dermatitis

Lilly, I4V-MC-JAIR(c), A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Severe or Very Severe Alopecia Areata

Galderma, RD.06.SPR.118161, A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis

Galderma, RD.06.SPR.118163, A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis

Janssen, CNTO1959PSO3001, A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis

LeoPharma, LP0133-1275, A phase 2b, double-blind, randomised, 5-arm, vehicle-controlled, dose-ranging trial to evaluate the efficacy and safety of twice daily topical applications of delgocitinib cream 1, 3, 8, 20 mg/g for 8 weeks in adult subjects with mild to severe atopic dermatitis

LeoPharma, LP0162-1326, A Randomised, Double-blind, Placebo-Controlled, phase 3 trial to Evaluate the Efficancy and Safety of Tralokinumab Monotherapy in Subjects eith Moderate-to-Severe Atopic Dermatitis who are Candidates for Systemic Therapy

LeoPharma, LP0162-1334, A randomised, double-blind, placebo-controlled, parallel-group, multi-centre trial to evaluate the efficacy, safety, and tolerability of tralokinumab monotherapy in adolescent subjects with moderate-to-severe atopic dermatitis who are candidates for systemic therapy

Novartis, QGE031C2303, A multi-center, randomized, double-blind, active and placebo-controlled study to investigate the efficacy and safety of ligelizumab (QGE031) in the treatment of Chronic Spontaneous Urticaria (CSU) in adolescents and adults inadequately controlled with H1-antihistamines

Pfizer, B7451036, A phase 3, randomised, double-blind, placebo-controlled, multi-centre study investigating the efficacy and safety of PF-04965842  co-administered with background medicated topical therapy in adolescent participants 12 to <18 years of age with moderate-to-severe atopic dermatitis

Pfizer, B7451015, A phase 3 multi-center,long-term extensions study investigating the efficacy and safety of abrocitinib, with or without topical medications, administered to subjects aged 12 years and older with moderate to severe atopic dermatitis

Pfizer, B7981019, phase 2b randomised, double-blind, placebo-controlled, multicenter, dose-ranging study to evaluiate the efficacy and safety profile of PF-06651600 with a partially blinded extension period to evaluate the efficacy and safety of PF-06651600 AND PF-06700841 in subjects with active non-segmental vitiligo

Pfizer, C2501007, phase 2A multicenter, randomized, double-blind, placebo-controlled, 16-week study evalutating the safety and efficacy of PF-06650833, PF-06700841, and PF-06826647 in adults with moderate to severe hidradenitits suppurativa